Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel
NASDAQ:BLRX

BioLineRx Q1 2026 Earnings Report

BioLineRx logo
$3.04 0.00 (0.00%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$3.04 +0.00 (+0.16%)
As of 05/5/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

BioLineRx EPS Results

Actual EPS
N/A
Consensus EPS
-$1.04
Beat/Miss
N/A
One Year Ago EPS
N/A

BioLineRx Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.34 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioLineRx Announcement Details

Quarter
Q1 2026
Date
5/26/2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 26, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

BioLineRx Earnings Headlines

BioLineRx (NASDAQ:BLRX) Shares Cross Above Two Hundred Day Moving Average - Here's Why
May 5 at 3:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30759073
BioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
April 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68325353-biolinerx-ltd-hemispherian-as-biolinerx-and-hemispherian-announce-first-patient-dosed-in-phase-1-2a-study-of-glix1-for-the-treatment-of-glioblastom-008.htm
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
 |  InvestorPlace (Ad)
BLRX stock surges pre-market on cancer trial catalyst – eyes 50-DMA breakout for first time in nearly 2 months
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/blrx-stock-surges-pre-market-on-cancer-trial-catalyst-eyes-50-dma-breakout-for-first-time-in-nearly-2-months/ar-AA21UHYo
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
April 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-announce-first-patient-dosed-in-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302755515.html
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
April 8, 2026  |  marketwatch.comhttps://www.marketwatch.com/press-release/hemispherian-initiates-phase-1-2a-clinical-trial-of-glix1-in-glioblastoma-7a4ec9fa
See More BioLineRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLineRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your email.

About BioLineRx

BioLineRx (NASDAQ:BLRX) (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors. In immunology and inflammatory diseases, the company is developing novel agents that modulate key biological pathways to reduce disease activity with minimal side effects. BioLineRx also explores treatments for neuropathic pain and other central nervous system conditions, seeking to offer new therapeutic options where few effective treatments exist.

Headquartered in Modi’in, Israel, BioLineRx maintains strategic partnerships and licensing arrangements across North America, Europe and Asia to support its global development efforts. By leveraging a business model that combines in-licensing, co-development and out-licensing of assets, the company aims to maximize the value of its pipeline while managing development risk. BioLineRx collaborates with contract research organizations and clinical centers worldwide to conduct multi-site trials and accelerate the advancement of its drug candidates.

View BioLineRx Profile
Earnings Tools